Dottikon ES Holding AG Logo

Dottikon ES Holding AG

Manufactures chemicals and APIs, specializing in hazardous reactions.

DESN | SW

Overview

Corporate Details

ISIN(s):
CH0582581713
LEI:
50670064H782SV8G2Z44
Country:
Switzerland
Address:
Hembrunnstrasse 17, 5605 Dottikon

Description

Dottikon ES Holding AG manufactures high-quality performance chemicals, intermediates, and exclusive active pharmaceutical ingredients (APIs) for the chemical, biotech, and pharmaceutical industries. The company specializes in hazardous reactions, positioning itself as a strategic development and manufacturing partner. Its services encompass research and development, route finding, process development, and process intensification. Dottikon operates multi-ton production facilities under cGMP standards, with approvals from regulatory bodies including the FDA and Swissmedic, managing the entire product lifecycle from development to large-scale manufacturing.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Dottikon ES Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Dottikon ES Holding AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Dottikon ES Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-06-18 N/A Executive member Sell None 19,500,000.00 CHF
2023-07-24 N/A Executive member Sell None 72,600.00 CHF
2023-06-15 N/A Executive member Sell None 85,872,280.00 CHF
2023-06-15 N/A Non-Executive member Buy None 26,000.00 CHF
2023-06-01 N/A Non-Executive member Buy None 30,240.00 CHF

Peer Companies

Acurx Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing a new class of antibiotics for priority pathogens.
United States of America
ACXP
Adaptimmune Therapeutics PLC Logo
Commercial-stage biopharma developing TCR T-cell therapies for solid tumors.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops IgY-based immune antibodies as alternatives to vaccines and antibiotics.
South Korea
179530
ADC Therapeutics SA Logo
Commercial-stage biotech developing antibody-drug conjugates for cancer therapy.
United States of America
ADCT
Addex Therapeutics Ltd. Logo
Clinical-stage biopharma developing allosteric modulators for neurological disorders.
Switzerland
ADXN
ADIAL PHARMACEUTICALS, INC. Logo
A clinical-stage biopharma developing genetically targeted therapies for addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Develops allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
Adlai Nortye Ltd. Logo
A clinical-stage biopharma firm developing cancer immunotherapies and RAS-targeting drugs.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
Biopharmaceutical company that develops and manufactures plasma-derived biologics.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
A clinical-stage company developing gene therapies for ocular diseases.
United States of America
ADVM

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.